Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase I/II trial of fenretinide (4-HPR) + rituximab in patients with B-cell lymphoma.

Trial Profile

A phase I/II trial of fenretinide (4-HPR) + rituximab in patients with B-cell lymphoma.

Phase of Trial: Phase I/II

Latest Information Update: 01 Feb 2017

At a glance

  • Drugs Fenretinide (Primary) ; Rituximab
  • Indications B cell lymphoma; Burkitt's lymphoma; Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Hodgkin's disease; Lymphoma; Mantle-cell lymphoma; Non-Hodgkin's lymphoma; Waldenstrom's macroglobulinaemia
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 08 Dec 2015 Results presented at the 57th Annual Meeting and Exposition of the American Society of Hematology
    • 31 Jul 2013 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top